Sneek Peak: Pilgrim Jackson on Yatiri Bio and decoding proteins to predict treatment response

What if you could know before enrolling a single patient which ones will actually respond to treatment?Pilgrim Jackson, CEO of Yatiri Bio, is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far—potentially cutting Phase 2 trials from 100 patients to just 40.🎙️ Full episode drops December 18In the complete interview, we dive into:• Proteomic signatures that differentiate responders from non-responders• De-risking clinical trials and addressing patient heterogeneity• Regulatory strategy for biomarker-driven trials• The future of precision oncologySubscribe so you don't miss it.#SneakPeek #ClinicalTrials #PrecisionMedicine #Proteomics